Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181


Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR.

Chest. 2012 Feb;141(2 Suppl):e419S-e496S. doi: 10.1378/chest.11-2301. Erratum in: Chest. 2012 Dec;142(6):1698-1704.


Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

MacLean S, Mulla S, Akl EA, Jankowski M, Vandvik PO, Ebrahim S, McLeod S, Bhatnagar N, Guyatt GH.

Chest. 2012 Feb;141(2 Suppl):e1S-e23S. doi: 10.1378/chest.11-2290. Review.


Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Guyatt GH, Norris SL, Schulman S, Hirsh J, Eckman MH, Akl EA, Crowther M, Vandvik PO, Eikelboom JW, McDonagh MS, Lewis SZ, Gutterman DD, Cook DJ, Schünemann HJ.

Chest. 2012 Feb;141(2 Suppl):53S-70S. doi: 10.1378/chest.11-2288.


Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE.

Warkentin TE, Davidson BL, Büller HR, Gallus A, Gent M, Lensing AWA, Piovella F, Prins MH, Segers AEM, Kelton JG.

Chest. 2011 Aug;140(2):366-373. doi: 10.1378/chest.10-1599. Epub 2011 Mar 10.


Fondaparinux: does it cause HIT? Can it treat HIT?

Warkentin TE.

Expert Rev Hematol. 2010 Oct;3(5):567-81. doi: 10.1586/ehm.10.54. Review.


A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study.

Boyce SW, Bandyk DF, Bartholomew JR, Frame JN, Rice L.

Am J Ther. 2011 Jan;18(1):14-22. doi: 10.1097/MJT.0b013e3181f65503.


The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion.

Cuker A, Arepally G, Crowther MA, Rice L, Datko F, Hook K, Propert KJ, Kuter DJ, Ortel TL, Konkle BA, Cines DB.

J Thromb Haemost. 2010 Dec;8(12):2642-50. doi: 10.1111/j.1538-7836.2010.04059.x.


Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials.

Lee MS, Liao H, Yang T, Dhoot J, Tobis J, Fonarow G, Mahmud E.

Int J Cardiol. 2011 Nov 3;152(3):369-74. doi: 10.1016/j.ijcard.2010.08.007. Epub 2010 Sep 16. Review.


Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke.

Salem M, Elrefai S, Shrit MA, Warkentin TE.

Thromb Haemost. 2010 Nov;104(5):1071-2. doi: 10.1160/TH10-05-0284. Epub 2010 Aug 30. No abstract available.


Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery.

Selleng S, Malowsky B, Itterman T, Bagemühl J, Wessel A, Wollert HG, Warkentin TE, Greinacher A.

Am Heart J. 2010 Aug;160(2):362-9. doi: 10.1016/j.ahj.2010.05.026.


Fondaparinux as an alternative anticoagulant therapy during pregnancy.

Knol HM, Schultinge L, Erwich JJ, Meijer K.

J Thromb Haemost. 2010 Aug;8(8):1876-9. doi: 10.1111/j.1538-7836.2010.03926.x. Epub 2010 May 21. No abstract available.


Non-necrotizing heparin-induced skin lesions and the 4T's score.

Warkentin TE, Linkins LA.

J Thromb Haemost. 2010 Jul;8(7):1483-5. doi: 10.1111/j.1538-7836.2010.03880.x. Epub 2010 Apr 8. No abstract available.


Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia.

Refaai MA, Chuang C, Menegus M, Blumberg N, Francis CW.

J Thromb Haemost. 2010 Jun;8(6):1419-21. doi: 10.1111/j.1538-7836.2010.03861.x. Epub 2010 Mar 19. No abstract available.


The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients.

Crowther MA, Cook DJ, Albert M, Williamson D, Meade M, Granton J, Skrobik Y, Langevin S, Mehta S, Hebert P, Guyatt GH, Geerts W, Rabbat C, Douketis J, Zytaruk N, Sheppard J, Greinacher A, Warkentin TE; Canadian Critical Care Trials Group.

J Crit Care. 2010 Jun;25(2):287-93. doi: 10.1016/j.jcrc.2009.12.006. Epub 2010 Feb 10.


Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia.

Wanaka K, Matsuo T, Matsuo M, Kaneko C, Miyashita K, Asada R, Matsushima H, Nakajima Y.

J Thromb Haemost. 2010 Mar;8(3):616-8. doi: 10.1111/j.1538-7836.2009.03734.x. Epub 2009 Dec 24. No abstract available.


Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization.

Warkentin TE, Cook RJ, Marder VJ, Greinacher A.

J Thromb Haemost. 2010 Mar;8(3):504-12. doi: 10.1111/j.1538-7836.2009.03735.x. Epub 2009 Dec 24.


The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia.

Lubenow N, Hinz P, Thomaschewski S, Lietz T, Vogler M, Ladwig A, Jünger M, Nauck M, Schellong S, Wander K, Engel G, Ekkernkamp A, Greinacher A.

Blood. 2010 Mar 4;115(9):1797-803. doi: 10.1182/blood-2009-07-231506. Epub 2009 Nov 20.


A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis.

Magnani HN.

Thromb Res. 2010 Apr;125(4):e171-6. doi: 10.1016/j.thromres.2009.10.008. Epub 2009 Nov 18. Review.


Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.

Grouzi E, Kyriakou E, Panagou I, Spiliotopoulou I.

Clin Appl Thromb Hemost. 2010 Dec;16(6):663-7. doi: 10.1177/1076029609347900. Epub 2009 Oct 13.


Supplemental Content

Support Center